Liposomal annamycin, a next generation anthracycline that overcomes mdr and has no cardiotoxicity with preliminary efficacy in the treatment of r/r aml
Introduction: Anthracyclines with cytarabine has remained the backbone for induction therapy in the treatment of AML since the 1970's. Annamycin, a new anthracycline formulated in a nanomolecular bi-lamellar liposomes, was developed and has been shown both in preclinical and clinical studies to...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-09-01
|
| Series: | Hematology Reports |
| Online Access: | https://www.pagepress.org/journals/index.php/hr/article/view/8912 |